NovaBridge Biosciences NBP
NASDAQ NBP
$1.80 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

NovaBridge Biosciences (NBP) Free Cash Flow (2019 - 2025)

NovaBridge Biosciences (NBP) posted quarterly Free Cash Flow of -$14.6 million for Q4 2025, down 33.77% year-over-year from -$22.0 million in Q4 2024, and down 893.69% quarter-over-quarter from $1.8 million in Q3 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

NovaBridge Biosciences (NBP) Free Cash Flow (2019 - 2025) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Free Cash Flow for 4 consecutive years, with -$14.6 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Free Cash Flow fell 33.77% year-over-year to -$14.6 million; the TTM figure through Dec 2025 stood at -$12.8 million (down 412.74% YoY), while the FY2025 annual figure was -$20.6 million, up 60.87% from the prior year.
  • Free Cash Flow declined to -$14.6 million in Q4 2025 per NBP's latest filing, from $1.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $8.4 million in Q3 2024 and bottomed at -$14.6 million in Q4 2025.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.01 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 572.80 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -563.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -389.61 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 437.80 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 292.04 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 477.44 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -95.09 Mn
10 NovaBridge Biosciences 197.68 Mn 197.68 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -14.60 Mn
Sep 30, 2025 1.99 Mn
Dec 31, 2024 -10.91 Mn
Sep 30, 2024 8.42 Mn
Dec 31, 2020 153.83 Mn
Sep 30, 2020 668,359.95
Dec 31, 2019 -29.56 Mn